BAJAJ BROKING

Notification close image
No new Notification messages
card image
Borana Weaves IPO is Open!
Apply for the Borana Weaves IPO through UPI in just minutes.
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Cipla Receives US FDA Form 483 for Goa Facility Inspection

Synopsis:

Cipla's Medispray unit in Goa received one US FDA Form 483 observation after a detailed inspection. The company is addressing the issue within FDA timelines. Cipla share price closed at ₹1,445.90 on January 20, 2025, marginally up by 0.24%.

Cipla news today

Pharmaceutical giant Cipla announced that the US FDA inspected its subsidiary Medispray Laboratories in Kundaim, Goa, between 14-20 January 2025. Following the inspection, the facility received a single observation documented in Form 483. Cipla assured stakeholders of its commitment to addressing the observation promptly within the stipulated timeline, ensuring strict adherence to Good Manufacturing Practices (GMP).

Also read: RBI Forms External Advisory Committee for Universal and Small Finance Banks

CIPLA LTD

Trade

1482.428.00 (1.92 %)

Updated - 21 May 2025
1491.00day high
DAY HIGH
1454.60day low
DAY LOW
2001251
VOLUME (BSE)

Key Takeaways:

  • Facility Location: Medispray Laboratories, Kundaim, Goa

  • Inspection Period: 14-20 January 2025

  • Observation: One Form 483 issued by the US FDA

  • Action Plan: Cipla will respond to the FDA within 15 days

  • Cipla Share Price: Closed at ₹1,445.90 on January 20, 2025

Also read: TCS Opens AI-Powered Delivery Centre in France for Aerospace

What Is Form 483?

Form 483, issued by the US FDA, lists observations made during inspections regarding potential deviations from GMP. It is not a final determination but serves as a preliminary communication. Companies receiving Form 483 have 15 days to submit corrective actions to the FDA, showcasing their compliance plan.

Inspection Details

Information

Facility Name

Medispray Laboratories

Location

Kundaim, Goa

Inspection Duration

14-20 January 2025

Observations (Form 483)

1

Cipla Share Price Movement

On the day of the announcement, Cipla share price ended at ₹1,445.90, marking a 0.24% increase. Investors are monitoring the situation as Cipla’s commitment to GMP compliance and prompt issue resolution reflects its operational reliability.

Cipla’s Response Plan

Cipla emphasised its proactive approach, stating that the observation would be addressed comprehensively within the stipulated timeline. This reflects Cipla’s strong compliance framework and its dedication to maintaining FDA standards.

The US FDA Form 483 observation highlights areas requiring attention but does not indicate significant non-compliance. Cipla’s transparent communication and swift corrective measures underscore its focus on regulatory adherence, instilling confidence in stakeholders. With a resilient operational framework, Cipla remains poised to resolve the issue efficiently.

Also read: Reliance Power Appoints Neeraj Parakh as CEO for Three Years

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|